{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:25:19Z","timestamp":1794270319634,"version":"4.9.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32272960"],"award-info":[{"award-number":["32272960"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFD1800505"],"award-info":[{"award-number":["2022YFD1800505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.arr.2026.103337","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:58Z","timestamp":1787669998000},"page":"103337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Vaccination strategies in neurodegenerative proteinopathies"],"prefix":"10.1016","volume":"122","author":[{"given":"Chunhao","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5175-7589","authenticated-orcid":false,"given":"Lifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2026.103337_bib1","doi-asserted-by":"crossref","first-page":"19812","DOI":"10.1074\/jbc.RA118.004810","article-title":"Recombinant prion protein vaccination of transgenic elk PrP mice and reindeer overcomes self-tolerance and protects mice against chronic wasting disease","volume":"293","author":"Abdelaziz","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2026.103337_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1014166","article-title":"Prion shedding is reduced by chronic wasting disease vaccination","volume":"22","author":"Ahmed-Hassan","year":"2026","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.arr.2026.103337_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14342","article-title":"The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer\u2019s disease based on clearcut biomarker evidence","volume":"21","author":"Aisen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.arr.2026.103337_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2174\/1567205012666150302154121","article-title":"Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer\u2019s disease: results from two phase 2 studies","volume":"12","author":"Arai","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2026.103337_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1099\/vir.0.013417-0","article-title":"Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie","volume":"91","author":"Bachy","year":"2010","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.arr.2026.103337_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41380-021-01385-7","article-title":"Discovery of a novel pseudo \u03b2-hairpin structure of N-truncated amyloid-\u03b2 for use as a vaccine against Alzheimer\u2019s disease","volume":"27","author":"Bakrania","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2026.103337_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2026.103148","article-title":"Co-aggregation of amyloidogenic proteins in age-related neurodegenerative diseases","volume":"118","author":"Basha","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103337_bib9","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","article-title":"Pyroglutamate A\u03b2 cascade as drug target in Alzheimer\u2019s disease","volume":"27","author":"Bayer","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2026.103337_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/alz.075159","article-title":"Synucleinopathy in Alzheimer\u2019s disease: role of the alpha-synuclein seed amplification assays","volume":"19","author":"Bellomo","year":"2023","journal-title":"Alzheimer\u2019S. & Dement."},{"key":"10.1016\/j.arr.2026.103337_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105122","article-title":"Flanking regions, amyloid cores, and polymorphism: the potential interplay underlying structural diversity","volume":"299","author":"Bhopatkar","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2026.103337_bib12","article-title":"VXX-301, a muti-epitope active immunotherapy targeting Tau, induces antibodies with favorable binding to Tau and exhibits efficacy in vivo","volume":"20","author":"Boyd","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.arr.2026.103337_bib14","doi-asserted-by":"crossref","DOI":"10.1590\/s1678-9946202466004","article-title":"The decline of measles antibody titers in previously vaccinated adults: a cross-sectional analysis","volume":"66","author":"Casti\u00f1eiras","year":"2024","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.arr.2026.103337_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103652","article-title":"CRISPR-Cas9 in Alzheimer\u2019s disease: therapeutic trends, modalities, and challenges","volume":"28","author":"Chacko","year":"2023","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.arr.2026.103337_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/acschemneuro.2c00539","article-title":"Evaluation of an adoptive cellular therapy-based vaccine in a transgenic mouse model of \u03b1-synucleinopathy","volume":"14","author":"Chu","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2026.103337_bib17","doi-asserted-by":"crossref","first-page":"15383","DOI":"10.3390\/ijms232315383","article-title":"Tau isoforms: gaining insight into MAPT alternative splicing","volume":"23","author":"Corsi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103337_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12264-022-00934-6","article-title":"Parkinson\u2019s disease: a multisystem disorder","volume":"39","author":"Costa","year":"2023","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.arr.2026.103337_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136477","article-title":"CRM197-scaffolded vaccines designed by epitope grafting ameliorate cognitive decline in an Alzheimer\u2019s disease model","volume":"281","author":"Cui","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.arr.2026.103337_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104923","article-title":"Efficacy assessment of an active tau immunotherapy in Alzheimer\u2019s disease patients with amyloid and tau pathology: a post hoc analysis of the \u201cADAMANT\u201d randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial","volume":"99","author":"Cullen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arr.2026.103337_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-016-0115-2","article-title":"Immunotherapy targeting pyroglutamate-3 A\u03b2: prospects and challenges","volume":"11","author":"Cynis","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2026.103337_bib22","article-title":"Therapeutic nanoliposome vaccine targeting multiple A\u03b2 and tau epitopes reduces AD-like brain pathologies and rescues cognitive deficits in 3xTg-AD mice","volume":"51","author":"Dai","year":"2026","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.arr.2026.103337_bib23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.vaccine.2017.03.020","article-title":"MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice","volume":"35","author":"Davtyan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2026.103337_bib24","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2026.103337_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-019-0556-2","article-title":"Testing a MultiTEP-based combination vaccine to reduce A\u03b2 and tau pathology in Tau22\/5xFAD bigenic mice","volume":"11","author":"Davtyan","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103337_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neurobiolaging.2017.08.006","article-title":"MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency","volume":"59","author":"Davtyan","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2026.103337_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/srep28912","article-title":"Alzheimer\u2019s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A\u03b2 pathological molecules","volume":"6","author":"Davtyan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2026.103337_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjmed.2025.11.025","article-title":"Advances in neurological therapies: a review of clinical trials in Alzheimer\u2019s, Parkinson\u2019s, and multiple sclerosis","volume":"139","author":"de Souza","year":"2026","journal-title":"Am. J. Med."},{"key":"10.1016\/j.arr.2026.103337_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181844","article-title":"Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles","volume":"12","author":"Doucet","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.arr.2026.103337_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/v13050811","article-title":"Vaccination with prion peptide-displaying polyomavirus-like particles prolongs incubation time in scrapie-infected mice","volume":"13","author":"Eiden","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.arr.2026.103337_bib31","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2026.103337_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00401-026-03015-4","article-title":"A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann-Str\u00e4ussler-Scheinker disease mutation","volume":"151","author":"Fang","year":"2026","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2026.103337_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-024-00942-9","article-title":"A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer\u2019s disease in 3xTg mice","volume":"9","author":"Feng","year":"2024","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.arr.2026.103337_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70462","article-title":"Small-diffusible aggregates, plaques, tangles, and dynamic equilibria: untangling Alzheimer\u2019s disease","volume":"21","author":"Fertan","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib35","article-title":"A vaccine to prevent initial loss of cognition and eventual Alzheimer\u2019s disease in elderly persons","volume":"7","author":"Fessel","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10665","article-title":"Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson\u2019s disease and related disorders","volume":"9","author":"Flores-Fernandez","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.arr.2026.103337_bib37","article-title":"Norovirus P particle-based active A\u03b2 immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer\u2019s disease","volume":"7","author":"Fu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2026.103337_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/IJN.S499938","article-title":"A ferritin-based Eg95 nanoparticle vaccine adjuvanted with pCpG eliciting robust immune responses against cystic echinococcosis in mice model","volume":"20","author":"Gao","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.arr.2026.103337_bib39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert. Rev. Vaccin."},{"key":"10.1016\/j.arr.2026.103337_bib40","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.vaccine.2005.11.039","article-title":"Prototype Alzheimer\u2019s disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch","volume":"24","author":"Ghochikyan","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2026.103337_bib41","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1126\/science.adj9255","article-title":"Immunotherapies for Alzheimer\u2019s disease","volume":"382","author":"Golde","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.arr.2026.103337_bib42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.vaccine.2014.11.035","article-title":"Mucosal immunization with an attenuated Salmonella vaccine partially protects white-tailed deer from chronic wasting disease","volume":"33","author":"Go\u00f1i","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2026.103337_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2013.06.018","article-title":"Reduction of cerebral A\u03b2 burden and improvement in cognitive function in Tg-APPswe\/PSEN1dE9 mice following vaccination with a multivalent A\u03b23-10 DNA vaccine","volume":"549","author":"Guo","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2026.103337_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102192","article-title":"Passive immunotherapy for Alzheimer\u2019s disease","volume":"94","author":"Guo","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2026.103337_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/13872877251375985","article-title":"Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer\u2019s disease: post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial","volume":"108","author":"Haaland","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103337_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/vaccines12060659","article-title":"mRNA vaccine for Alzheimer\u2019s disease: pilot study","volume":"12","author":"Hovakimyan","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.arr.2026.103337_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41541-022-00544-3","article-title":"Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates","volume":"7","author":"Hovakimyan","year":"2022","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.arr.2026.103337_bib48","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate alzheimer\u2019s disease","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2026.103337_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-025-01147-4","article-title":"pS396\/pS404 (PHF1) tau vaccine outperforms pS199\/pS202 (AT8) in rTg4510 tauopathy model","volume":"10","author":"Hulse","year":"2025","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.arr.2026.103337_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib51","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2019.7437","article-title":"Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia","volume":"321","author":"Jack","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2026.103337_bib52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2026.103337_bib53","article-title":"Expanding spectrum of prion diseases","volume":"4","author":"Ji","year":"2020","journal-title":"Emerg. Top. life Sci."},{"key":"10.1016\/j.arr.2026.103337_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2024.09.012","article-title":"Amyloid-\u03b2-targeting immunotherapies for Alzheimer\u2019s disease","volume":"375","author":"Jin","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.arr.2026.103337_bib55","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","article-title":"Alzheimer\u2019s disease: from immunotherapy to immunoprevention","volume":"186","author":"Jucker","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.arr.2026.103337_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202207719","article-title":"A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for alzheimer\u2019s disease","volume":"35","author":"Jung","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.arr.2026.103337_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41514-026-00397-3","article-title":"Nasal administration of Protollin enhances monocyte phagocytosis and decreases CD8+\u2009T cell cytotoxicity in subjects with early Alzheimer\u2019s disease: a Phase 1 clinical trial","author":"Kolypetri","year":"2026","journal-title":"NPJ Aging"},{"key":"10.1016\/j.arr.2026.103337_bib58","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13195-024-01620-7","article-title":"Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer\u2019s disease, positive for plasma p-tau217","volume":"16","author":"Kovacech","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103337_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer\u2019s disease vaccine","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.arr.2026.103337_bib60","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1038\/s41467-023-39328-1","article-title":"Specific post-translational modifications of soluble tau protein distinguishes Alzheimer\u2019s disease and primary tauopathies","volume":"14","author":"Kyalu Ngoie Zola","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2026.103337_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2012.09.008","article-title":"A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation A\u03b242 DNA vaccine for Alzheimer disease","volume":"254","author":"Lambracht-Washington","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.arr.2026.103337_bib62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10571-011-9680-7","article-title":"DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer\u2019s disease as it diminishes antigen-specific Th1 and Th17 cell proliferation","volume":"31","author":"Lambracht-Washington","year":"2011","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.arr.2026.103337_bib63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2478\/s13380-012-0037-6","article-title":"Active DNA A\u03b242 vaccination as immunotherapy for Alzheimer disease","volume":"3","author":"Lambracht-Washington","year":"2012","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.arr.2026.103337_bib64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1750-1326-8-36","article-title":"Immunotherapy for Alzheimer\u2019s disease: hoops and hurdles","volume":"8","author":"Lemere","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2026.103337_bib65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0002-9440(10)63296-8","article-title":"Alzheimer\u2019s disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet","volume":"165","author":"Lemere","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.arr.2026.103337_bib66","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1023\/A:1023203122036","article-title":"Amyloid-beta immunization in Alzheimer\u2019s disease transgenic mouse models and wildtype mice","volume":"28","author":"Lemere","year":"2003","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.arr.2026.103337_bib67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41589-020-00708-z","article-title":"Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease","volume":"17","author":"Li","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.arr.2026.103337_bib68","article-title":"Virus-like particles-based vaccine to combat neurodegenerative diseases","author":"Lim","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.arr.2026.103337_bib69","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1166\/jbn.2016.2256","article-title":"Polymer-encapsulated A\u03b2 peptide fragments as an oligomeric-specific vaccine for alzheimer\u2019s disease","volume":"12","author":"Lin","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.arr.2026.103337_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2026.106486","article-title":"Self-assembling ferritin nanoplatform enables amyloid-\u03b2-targeted immunotherapy and cognitive rescue in APP\/PS1 mice","volume":"135","author":"Liu","year":"2026","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.arr.2026.103337_bib71","doi-asserted-by":"crossref","first-page":"7771","DOI":"10.1038\/srep07771","article-title":"Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer\u2019s disease in PDAPP mice","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2026.103337_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-026-02082-9","article-title":"Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer\u2019s disease: randomised, controlled trial","author":"Lovr\u00f3","year":"2026","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103337_bib73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s11481-012-9371-2","article-title":"Efficacy of a therapeutic vaccine using mutated \u03b2-amyloid sensitized dendritic cells in Alzheimer\u2019s mice","volume":"7","author":"Luo","year":"2012","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.arr.2026.103337_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awag010","article-title":"Vaccines mimicking conformational epitopes on \u03b1-synuclein fibrils provide immunity to Parkinson\u2019s disease","author":"Ma","year":"2026","journal-title":"Brain"},{"key":"10.1016\/j.arr.2026.103337_bib75","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/j.vaccine.2004.11.067","article-title":"Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters","volume":"23","author":"Magri","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2026.103337_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115237","article-title":"Tailoring the antibody response to aggregated A\u00df using novel Alzheimer-vaccines","volume":"10","author":"Mandler","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.arr.2026.103337_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70101","article-title":"Targeting of phosphorylated tau at threonine 181 by a Q\u03b2 virus-like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques","volume":"21","author":"Maphis","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib78","doi-asserted-by":"crossref","first-page":"a029504","DOI":"10.1101\/cshperspect.a029504","article-title":"What is the predictive value of animal models for vaccine efficacy in humans?","volume":"10","author":"Martins","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.arr.2026.103337_bib79","series-title":"Current Hypotheses and Research Milestones in Alzheimer\u2019s Disease","first-page":"79","article-title":"Stages of pathological tau-protein processing in alzheimer\u2019s disease: from soluble aggregations to polymerization into insoluble Tau-PHFs","author":"Mena","year":"2009"},{"key":"10.1016\/j.arr.2026.103337_bib80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.conb.2020.01.009","article-title":"Preclinical biomarkers of prion infection and neurodegeneration","volume":"61","author":"Mok","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.arr.2026.103337_bib81","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/imm.12103","article-title":"CD4 T cells in immunity and immunotherapy of Alzheimer\u2019s disease","volume":"139","author":"Monsonego","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.arr.2026.103337_bib82","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.arr.2026.103337_bib83","first-page":"6","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy reprograms CNS immunity and alters Alzheimer\u2019s biomarkers: results from two open-label clinical trials","author":"Ms","year":"2026","journal-title":"Commun. Med."},{"key":"10.1016\/j.arr.2026.103337_bib84","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00441-023-03749-7","article-title":"Vaccines for prion diseases: a realistic goal?","volume":"392","author":"Napper","year":"2023","journal-title":"Cell. Tissue Res."},{"key":"10.1016\/j.arr.2026.103337_bib85","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/ma11071083","article-title":"Mesoporous silicon particles favor the induction of long-lived humoral responses in mice to a peptide-based vaccine","volume":"11","author":"Navarro-Tovar","year":"2018","journal-title":"Materials"},{"key":"10.1016\/j.arr.2026.103337_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-025-02952-w","article-title":"Alpha-synuclein deposition patterns in Alzheimer\u2019s disease: association with cortical amyloid beta and variable tau load","volume":"150","author":"Neubauer","year":"2025","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2026.103337_bib87","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.arr.2026.103337_bib88","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.arr.2026.103337_bib89","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14283\/jpad.2018.45","article-title":"AADvac1, an active immunotherapy for alzheimer\u2019s disease and non alzheimer tauopathies: an overview of preclinical and clinical development","volume":"6","author":"Novak","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103337_bib90","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.0600966103","article-title":"Nonviral Abeta DNA vaccine therapy against Alzheimer\u2019s disease: long-term effects and safety","volume":"103","author":"Okura","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2026.103337_bib91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.arr.2026.103337_bib92","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/vaccines11121820","article-title":"Immunization effects of a novel \u03b1-synuclein-based peptide epitope vaccine in Parkinson\u2019s disease-associated pathology","volume":"11","author":"Park","year":"2023","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.arr.2026.103337_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbi.2025.06.001","article-title":"A Novel A\u03b2 B-cell epitope Vaccine, A\u03b21-10 with carrier protein OVA and KLH reduce A\u03b2-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer\u2019s disease","volume":"129","author":"Park","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.arr.2026.103337_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70776","article-title":"Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against A\u03b240 in patients with mild cognitive impairment or very mild Alzheimer\u2019s disease: A randomized, double-blind, placebo-controlled phase 2 study","volume":"21","author":"Pascual-Lucas","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib95","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate alzheimer\u2019s disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2026.103337_bib96","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/brain\/awab129","article-title":"Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer\u2019s disease pathology in aged squirrel monkeys","volume":"144","author":"Patel","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.arr.2026.103337_bib97","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/brain\/awae061","article-title":"Vaccination with structurally adapted fungal protein fibrils induces immunity to Parkinson\u2019s disease","volume":"147","author":"Pesch","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.arr.2026.103337_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104823","article-title":"Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials","volume":"139","author":"Petrushina","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.arr.2026.103337_bib99","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s00210-025-04739-y","article-title":"Active immunization with bacteriophage AP205 VLPs results in reduced amyloid load and microgliosis in 5xFAD female mice","volume":"399","author":"Pilipenko","year":"2026","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.arr.2026.103337_bib100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neulet.2007.10.015","article-title":"Anti-prion activity generated by a novel vaccine formulation","volume":"429","author":"Pilon","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2026.103337_bib101","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7589\/2012-07-200","article-title":"Immunization with a synthetic peptide vaccine fails to protect mule deer (Odocoileus hemionus) from chronic wasting disease","volume":"49","author":"Pilon","year":"2013","journal-title":"J. Wildl. Dis."},{"key":"10.1016\/j.arr.2026.103337_bib102","first-page":"1079","article-title":"Safety and tolerability of active immunotherapy targeting \u03b1-synuclein with PD03A in patients with early Parkinson\u2019s disease: a randomized, placebo-controlled, phase 1 study","volume":"11","author":"Poewe","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2026.103337_bib103","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2174\/0929867323666160418114733","article-title":"Vaccination to Alzheimer disease. Is it a promising tool or a blind way?","volume":"23","author":"Pohanka","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.arr.2026.103337_bib104","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to Alzheimer\u2019s disease: clinical investigations into AN1792-associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.arr.2026.103337_bib105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with down syndrome: a phase 1b randomized clinical trial","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2026.103337_bib106","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41467-026-69289-0","article-title":"Recombinant zoster vaccine is associated with a reduced risk of dementia","volume":"17","author":"Rayens","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2026.103337_bib107","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/alz.13532","article-title":"Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE \u03b54 homozygotes","volume":"20","author":"Riviere","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib108","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.neurobiolaging.2003.12.020","article-title":"Lessons from the AN 1792 Alzheimer vaccine: lest we forget","volume":"25","author":"Robinson","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2026.103337_bib109","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrneurol.2012.258","article-title":"Immunotherapy in prion disease","volume":"9","author":"Roettger","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2026.103337_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2017.08.007","article-title":"APP\/A\u03b2 structural diversity and alzheimer\u2019s disease pathogenesis","volume":"110","author":"Roher","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.arr.2026.103337_bib111","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13195-018-0441-4","article-title":"Active full-length DNA A\u03b242 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology","volume":"10","author":"Rosenberg","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.arr.2026.103337_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004917","article-title":"Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie","volume":"4","author":"Rosset","year":"2009","journal-title":"PLOS One"},{"key":"10.1016\/j.arr.2026.103337_bib113","article-title":"Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older","volume":"22","author":"S","year":"2026","journal-title":"Alzheimer\u2019S. & Dement. J. Alzheimer\u2019S. Assoc."},{"key":"10.1016\/j.arr.2026.103337_bib114","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.181.1.768","article-title":"Contribution of antibody and T cell-specific responses to the progression of 139A-scrapie in C57BL\/6 mice immunized with prion protein peptides","volume":"181","author":"Sacquin","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.arr.2026.103337_bib115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.arr.2026.103337_bib116","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/vaccines10091432","article-title":"A novel C-type lectin receptor-targeted \u03b1-synuclein-based parkinson vaccine induces potent immune responses and therapeutic efficacy in mice","volume":"10","author":"Schmidhuber","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.arr.2026.103337_bib117","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2015.63","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE\u00ae AD02 in patients with early Alzheimer\u2019s disease","author":"Schneeberger","year":"2015","journal-title":"J. Prev. Alzheimers Dis. 2 103114"},{"key":"10.1016\/j.arr.2026.103337_bib118","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD)--from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.arr.2026.103337_bib119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(03)00907-8","article-title":"Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent","volume":"350","author":"Schwarz","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2026.103337_bib120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymthe.2022.11.002","article-title":"AAV-mediated neuronal expression of an scFv antibody selective for A\u03b2 oligomers protects synapses and rescues memory in Alzheimer models","volume":"31","author":"Selles","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.arr.2026.103337_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.arr.2026.103337_bib122","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/cells15100928","article-title":"Emerging therapeutic strategies for neurodegenerative diseases: a comprehensive review of recent advances and future directions","volume":"15","author":"Sepehrimanesh","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.arr.2026.103337_bib123","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(02)09513-2","article-title":"Postexposure prophylaxis against prion disease with a stimulator of innate immunity","volume":"360","author":"Sethi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2026.103337_bib124","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4103\/1673-5374.337054","article-title":"DNA vaccines targeting amyloid-\u03b2 oligomer ameliorate cognitive deficits of aged APP\/PS1\/tau triple-transgenic mouse models of Alzheimer\u2019s disease","volume":"17","author":"Sha","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.arr.2026.103337_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105940","article-title":"Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer\u2019s disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study","volume":"120","author":"Sol","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arr.2026.103337_bib126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbi.2024.08.028","article-title":"A pentavalent peptide vaccine elicits A\u03b2 and tau antibodies with prophylactic activity in an Alzheimer\u2019s disease mouse model","volume":"122","author":"Song","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.arr.2026.103337_bib127","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib128","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jamda.2016.06.009","article-title":"Active vaccines for alzheimer disease treatment","volume":"17","author":"Sterner","year":"2016","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.arr.2026.103337_bib129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(17)30037-6","article-title":"The prion model for progression and diversity of neurodegenerative diseases","volume":"16","author":"Stopschinski","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103337_bib130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-020-00416-z","article-title":"Norovirus P particle-based tau vaccine-generated phosphorylated tau antibodies markedly ameliorate tau pathology and improve behavioral deficits in mouse model of Alzheimer\u2019s disease","volume":"6","author":"Sun","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.arr.2026.103337_bib131","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-020-0172-y","article-title":"Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice","volume":"5","author":"Takeuchi","year":"2020","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.arr.2026.103337_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.115296","article-title":"Virus like nanoparticles of VLP-BSA-iRGD enhanced mucosal immune response by targeting M cells","volume":"259","author":"Tan","year":"2026","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.arr.2026.103337_bib133","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41541-024-00904-1","article-title":"Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers","volume":"9","author":"Tan","year":"2024","journal-title":"NPJ Vaccin."},{"key":"10.1016\/j.arr.2026.103337_bib134","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neurobiolaging.2019.03.016","article-title":"Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer\u2019s disease","volume":"79","author":"Timmers","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2026.103337_bib135","doi-asserted-by":"crossref","DOI":"10.1159\/000546287","article-title":"Active immunization targeting amyloid \u03b2 for the treatment of Alzheimer\u2019s disease","author":"Triplett","year":"2025","journal-title":"Neurodegener. Dis. 25 202217"},{"key":"10.1016\/j.arr.2026.103337_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71361","article-title":"Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer\u2019s disease: an update from the Alzheimer\u2019s Association ARIA workgroup","volume":"22","author":"van Etten","year":"2026","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.arr.2026.103337_bib137","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement. (N. Y"},{"key":"10.1016\/j.arr.2026.103337_bib138","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.arr.2026.103337_bib139","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.phrs.2003.12.028","article-title":"The role of beta amyloid in Alzheimer\u2019s disease: still a cause of everything or the only one who got caught?","volume":"50","author":"Verdile","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.arr.2026.103337_bib140","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103337_bib141","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/vaccines14060466","article-title":"A case report of a novel alpha-synuclein vaccine (TRB-001) in a Parkinson\u2019s patient: safe administration and induction of a high-titer, high-avidity functional antibody response","volume":"14","author":"Volc","year":"2026","journal-title":"Vaccines"},{"key":"10.1016\/j.arr.2026.103337_bib142","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac022","article-title":"An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer\u2019s disease: pyroglutamate amyloid beta","volume":"4","author":"Vukicevic","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.arr.2026.103337_bib143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.arr.2026.103337_bib144","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(08)70170-4","article-title":"Amyloid-beta immunisation for Alzheimer\u2019s disease","volume":"7","author":"Wisniewski","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.arr.2026.103337_bib145","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1016\/j.vaccine.2018.10.057","article-title":"Accelerated onset of chronic wasting disease in elk (Cervus canadensis) vaccinated with a PrPSc-specific vaccine and housed in a prion contaminated environment","volume":"36","author":"Wood","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.arr.2026.103337_bib146","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12865-019-0289-9","article-title":"Active immunization with norovirus P particle-based amyloid-\u03b2 chimeric protein vaccine induces high titers of anti-A\u03b2 antibodies in mice","volume":"20","author":"Yang","year":"2019","journal-title":"BMC Immunol."},{"key":"10.1016\/j.arr.2026.103337_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104665","article-title":"Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"94","author":"Yu","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.arr.2026.103337_bib148","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.3390\/ijms23116080","article-title":"Immunogenicity of MultiTEP-platform-based recombinant protein vaccine, PV-1950R, targeting three b-cell antigenic determinants of pathological \u03b1-synuclein","volume":"23","author":"Zagorski","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103337_bib149","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.3390\/ijms24129797","article-title":"Novel vaccine against pathological pyroglutamate-modified amyloid beta for prevention of alzheimer\u2019s disease","volume":"24","author":"Zagorski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2026.103337_bib150","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between A\u03b2 and Tau in the pathogenesis of alzheimer\u2019s disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.arr.2026.103337_bib151","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainresbull.2021.05.019","article-title":"Immunization with A\u03b23-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer\u2019s disease-like pathology in Tg-APPswe\/PSEN1dE9 mice","volume":"174","author":"Zhang","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2026.103337_bib152","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2024","journal-title":"Protein Cell."},{"key":"10.1016\/j.arr.2026.103337_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121690","article-title":"Blood-brain barrier permeable nanoparticles for Alzheimer\u2019s disease treatment by selective mitophagy of microglia","volume":"288","author":"Zhong","year":"2022","journal-title":"Biomaterials"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726003296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163726003296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:16:49Z","timestamp":1794269809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163726003296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":153,"alternative-id":["S1568163726003296"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2026.103337","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination strategies in neurodegenerative proteinopathies","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2026.103337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103337"}}